IL311710A - Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome - Google Patents
Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndromeInfo
- Publication number
- IL311710A IL311710A IL311710A IL31171024A IL311710A IL 311710 A IL311710 A IL 311710A IL 311710 A IL311710 A IL 311710A IL 31171024 A IL31171024 A IL 31171024A IL 311710 A IL311710 A IL 311710A
- Authority
- IL
- Israel
- Prior art keywords
- cd40l
- rheumatism
- prevention
- treatment
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249553P | 2021-09-28 | 2021-09-28 | |
| US202263375282P | 2022-09-12 | 2022-09-12 | |
| PCT/US2022/077182 WO2023056297A1 (en) | 2021-09-28 | 2022-09-28 | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311710A true IL311710A (en) | 2024-05-01 |
Family
ID=84360925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311710A IL311710A (en) | 2021-09-28 | 2022-09-28 | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240383991A1 (https=) |
| EP (1) | EP4408455A1 (https=) |
| JP (1) | JP2024535431A (https=) |
| KR (1) | KR20240101563A9 (https=) |
| AU (1) | AU2022358509A1 (https=) |
| CA (1) | CA3230926A1 (https=) |
| CL (2) | CL2024000881A1 (https=) |
| IL (1) | IL311710A (https=) |
| MA (1) | MA65537A1 (https=) |
| MX (1) | MX2024003954A (https=) |
| WO (1) | WO2023056297A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024152001A1 (en) * | 2023-01-13 | 2024-07-18 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome |
| KR20250162587A (ko) * | 2023-03-28 | 2025-11-18 | 비엘라 바이오, 인크. | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200074993A (ko) * | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| KR20260016618A (ko) * | 2018-09-26 | 2026-02-03 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2022
- 2022-09-28 MA MA65537A patent/MA65537A1/fr unknown
- 2022-09-28 JP JP2024519055A patent/JP2024535431A/ja active Pending
- 2022-09-28 KR KR1020247013785A patent/KR20240101563A9/ko active Pending
- 2022-09-28 AU AU2022358509A patent/AU2022358509A1/en active Pending
- 2022-09-28 EP EP22809606.1A patent/EP4408455A1/en active Pending
- 2022-09-28 CA CA3230926A patent/CA3230926A1/en active Pending
- 2022-09-28 MX MX2024003954A patent/MX2024003954A/es unknown
- 2022-09-28 IL IL311710A patent/IL311710A/en unknown
- 2022-09-28 WO PCT/US2022/077182 patent/WO2023056297A1/en not_active Ceased
-
2024
- 2024-03-21 US US18/612,452 patent/US20240383991A1/en active Pending
- 2024-03-26 CL CL2024000881A patent/CL2024000881A1/es unknown
-
2025
- 2025-03-03 CL CL2025000581A patent/CL2025000581A1/es unknown
- 2025-09-09 US US19/323,227 patent/US20260070997A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024003954A (es) | 2024-04-24 |
| MA65537A1 (fr) | 2025-06-30 |
| EP4408455A1 (en) | 2024-08-07 |
| CL2025000581A1 (es) | 2025-07-11 |
| WO2023056297A1 (en) | 2023-04-06 |
| JP2024535431A (ja) | 2024-09-30 |
| US20240383991A1 (en) | 2024-11-21 |
| CA3230926A1 (en) | 2023-04-06 |
| CL2024000881A1 (es) | 2024-09-13 |
| US20260070997A1 (en) | 2026-03-12 |
| KR20240101563A (ko) | 2024-07-02 |
| AU2022358509A1 (en) | 2024-03-28 |
| KR20240101563A9 (ko) | 2025-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282727A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| HUE045137T2 (hu) | HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek | |
| DK3504210T3 (da) | 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion | |
| IL281394A (en) | Method and composition for preventing and treating atherosclerosis and related diseases | |
| IL269083A (en) | Methods for preventing and treating heart disease | |
| EP3728279A4 (en) | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | |
| DK4225297T3 (da) | Kombinationsbehandling til behandling af cancer | |
| IL311710A (en) | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome | |
| IL282273A (en) | Urea derivatives for treating and/or preventing cancer | |
| IL286437A (en) | Materials and methods for enhanced treatment and prevention of biofilms | |
| EP3966320A4 (en) | Treatment and detection of inherited neuropathies and associated disorders | |
| IL284124A (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| EP3615547A4 (en) | TREATMENT AND PREVENTION OF KIDNEY DAMAGE | |
| IL310870A (en) | Quinazoline compounds for treatment of disease | |
| EP3558335A4 (en) | INHIBITION OF CASPASE-1 AND ITS USES IN THE PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | |
| EP4069847A4 (en) | Treatment of lower airways disorders | |
| EP4041275A4 (en) | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY DAMAGE | |
| IT201700109080A1 (it) | Composizione per la prevenzione e/o il trattamento delle affezioni delle vie respiratorie | |
| IL312885A (en) | Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma | |
| MA55467A (fr) | Utilisations thérapeutiques de dulaglutide | |
| SG11202008791UA (en) | Agent for prevention and/or treatment of pseudomonas aeruginosa infection | |
| EP4203954A4 (en) | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | |
| IL281447A (en) | Methods and compositions for treating viral infections | |
| EP3377062C0 (en) | AMINONAPHTHOQUINONE COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES | |
| EP3758739C0 (en) | TREATMENT AND PREVENTION OF PRE-ECLAMPSIA |